Table 2 Overview of assessments of technologies
From: An assessment of the future impact of alternative technologies on antibiotics markets
Assessment process: | Literature review | Industry expert MCDA | Clinicians roundtable discussion | Summary score | |||
|---|---|---|---|---|---|---|---|
Assessment parameter: | Potential to deliver products | Potential to reduce demand | Potential to impact on clinical use | Overall potential | |||
Assessment criteria, or score: | In clinical use | Products in pipeline | Targets priority pathogen (CDC list) | Score (max 27, min 6) | Assessment* | May reduce antibiotics demand | |
Rapid point-of-care diagnostics | Yes | Yes | Yes | 20.0 | High | Yes | High |
Vaccines | Yes | Yes | Yes | 14.8 | High | Yes | High |
Probiotics | No | Yes | Yes | 15.4 | High | Yes | Medium |
Fecal microbiota transplantation | No | Yes | Yes | 15.0 | High | Yes | Medium |
Therapeutic antibodies | Yes | Yes | Yes | 15.1 | High | No | Low |
Antimicrobial peptides | Yes | Yes | Yes | 11.4 | Low | No | Low |
Antibiotic biomaterials | Yes | No | n.a. | 12.4 | Low | Yes | Low |
Antimicrobial nanoparticles | Yes | Yes | No | 8.0 | Low | No | Low |
Anti-virulence materials | No | No | n.a. | 12.0 | Low | No consensus | Low |
Bacteriophages (and lysins) | No | Yes | Yes | 8.8 | Low | No | Low |